91st Annual Meeting of the American Thyroid Association

Safety

The safety of our event attendees is extremely important to the American Thyroid Association (ATA).  After careful consideration, ATA will require all attendees to be fully vaccinated for COVID-19 and to provide valid proof of vaccination.  Boosters are strongly recommended.  The ATA will be using a third party vendor for vaccine verification.

The Centers for Disease Control and Prevention (CDC) currently defines “fully vaccinated” as:

  • Two weeks after receiving the second dose in a two-dose series, such as the Pfizer, Moderna, AstraZeneca/Oxford, Sinopharm, Sinovac, and COVAXIN vaccines; or
  • Two weeks after receiving a single-dose vaccine, such as the Janssen (Johnson & Johnson) vaccine

If the CDC’s definition of “fully vaccinated” is revised, the ATA’s policy will be adjusted to reflect the most current public health and safety guidelines.

As of April 8, 2022, the WHO has said that the following vaccines meet the necessary criteria for safety and efficacy (learn more):

For anyone unable to attend the in-person event, the ATA is offering “ATA From Home”.  Session recordings from the Plenary Sessions, Award Lectures and select MTPs and symposia will be available through on-demand access after the event.  The available symposia and MTPs are:

  • Universal Screening for Thyroid Dysfunction in Pregnancy: An Ongoing Debate
  • MTP: Metastatic thyroid cancer-stepwise management
  • Minimally invasive approaches to thyroid nodules and cancer, including RFA
  • Thyroid Disease in Women: Understanding Sex-based Differences.
  • Long-term methimazole in Graves’ disease – yay or nay?
  • For and against T3/T4 combination therapy in hypothyroidism

Important Dates

June 12 – July 29, 2022:
Late Breaking Abstract Submissions Open

September 12, 2022:
Housing Deadline